Trump Cuts Prices on Ozempic and Wegovy in Deal With GLP-1 Weight Loss Drug Makers

The Trump administration announced a deal aimed at lowering the prices of GLP-1 weight loss drugs, Ozempic and Wegovy, significantly reducing costs for American patients. The agreement with drug manufacturers Eli Lilly and Novo Nordisk will bring monthly prices down to around $250, with new drugs to be launched at a capped price of $149. Importantly, Medicare will now cover these medications, with patient co-pays set at approximately $50 per month. This coverage targets around 10% of Medicare beneficiaries based on their body mass index and pre-existing health conditions. The administration plans to promote access through a new federal purchasing option, allowing consumers to buy GLP-1 drugs via a government portal called 'TrumpRX'. This initiative is expected to compete with insurers who have been slow to cover these drugs due to past high costs. President Trump emphasized the historic nature of this agreement and anticipated major U.S. manufacturing-led expansions by the involved companies, with the changes expected to take effect mid-next year.

Source 🔗